Comparative Pharmacology
Head-to-head clinical analysis: NITROGLYCERIN IN DEXTROSE 5 versus TRIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROGLYCERIN IN DEXTROSE 5 versus TRIDIL.
NITROGLYCERIN IN DEXTROSE 5% vs TRIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels and causing venous and arterial dilation.
Nitroglycerin is a vasodilator that acts directly on vascular smooth muscle, causing relaxation. It primarily dilates venous capacitance vessels, reducing preload, and at higher doses dilates arterioles, reducing afterload. The mechanism involves nitric oxide-mediated activation of guanylyl cyclase, increasing cGMP levels.
Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.
Initial adult dose: 5 mcg/min IV via continuous infusion, titrated by 5 mcg/min every 3-5 minutes to achieve desired effect; usual therapeutic range 10-200 mcg/min.
None Documented
None Documented
Terminal elimination half-life: 1–4 minutes; clinical context: rapid clearance due to extensive metabolism by glutathione-S-transferase and glutathionylation.
Terminal elimination half-life of nitroglycerin is 1-4 minutes; clinical effects are limited by rapid metabolism
Renal: ~33% as intact drug; hepatic metabolism accounts for >90% of clearance; biliary/fecal: negligible.
Renal (87% as inorganic nitrite/nitrate and metabolites), biliary/fecal (minimal, <1%)
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator